Citadel Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.69M | Sell |
72,400
-64,800
| -47% | -$1.41M | ﹤0.01% | 6462 |
|
|
2025
Q4 | $2.88M | Buy |
137,200
+29,600
| +28% | +$516K | ﹤0.01% | 5239 |
|
|
2025
Q3 | $1.66M | Buy |
107,600
+28,800
| +37% | +$377K | ﹤0.01% | 6459 |
|
|
2025
Q2 | $738K | Sell |
78,800
-8,000
| -9% | -$88.1K | ﹤0.01% | 7734 |
|
|
2025
Q1 | $1.07M | Sell |
86,800
-40,100
| -32% | -$566K | ﹤0.01% | 6821 |
|
|
2024
Q4 | $1.68M | Buy |
126,900
+88,900
| +234% | +$1.52M | ﹤0.01% | 5986 |
|
|
2024
Q3 | $732K | Buy |
38,000
+13,000
| +52% | +$269K | ﹤0.01% | 7459 |
|
|
2024
Q2 | $513K | Sell |
25,000
-13,100
| -34% | -$274K | ﹤0.01% | 7988 |
|
|
2024
Q1 | $907K | Sell |
38,100
-500
| -1% | -$11.2K | ﹤0.01% | 7122 |
|
|
2023
Q4 | $834K | Sell |
38,600
-122,100
| -76% | -$1.88M | ﹤0.01% | 7037 |
|
|
2023
Q3 | $2.33M | Buy |
160,700
+159,300
| +11,379% | +$3.01M | ﹤0.01% | 4934 |
|
|
2023
Q2 | $29.3K | Sell |
1,400
-1,600
| -53% | -$33.3K | ﹤0.01% | 12376 |
|
|
2023
Q1 | $63.4K | Sell |
3,000
-46,000
| -94% | -$1.14M | ﹤0.01% | 11853 |
|
|
2022
Q4 | $1.25M | Sell |
49,000
-42,900
| -47% | -$1M | ﹤0.01% | 6388 |
|
|
2022
Q3 | $2.21M | Sell |
91,900
-5,400
| -6% | -$121K | ﹤0.01% | 5403 |
|
|
2022
Q2 | $1.87M | Buy |
97,300
+44,200
| +83% | +$736K | ﹤0.01% | 5669 |
|
|
2022
Q1 | $923K | Buy |
53,100
+41,600
| +362% | +$700K | ﹤0.01% | 7895 |
|
|
2021
Q4 | $252K | Sell |
11,500
-5,800
| -34% | -$107K | ﹤0.01% | 11335 |
|
|
2021
Q3 | $331K | Sell |
17,300
-18,800
| -52% | -$313K | ﹤0.01% | 10854 |
|
|
2021
Q2 | $620K | Buy |
36,100
+24,500
| +211% | +$449K | ﹤0.01% | 9536 |
|
|
2021
Q1 | $259K | Sell |
11,600
-6,000
| -34% | -$136K | ﹤0.01% | 11167 |
|
|
2020
Q4 | $391K | Sell |
17,600
-13,300
| -43% | -$276K | ﹤0.01% | 8613 |
|
|
2020
Q3 | $456K | Sell |
30,900
-21,600
| -41% | -$329K | ﹤0.01% | 7465 |
|
|
2020
Q2 | $778K | Buy |
52,500
+26,600
| +103% | +$405K | ﹤0.01% | 6289 |
|
|
2020
Q1 | $284K | Buy |
25,900
+12,700
| +96% | +$119K | ﹤0.01% | 7438 |
|
|
2019
Q4 | $116K | Buy |
13,200
+1,200
| +10% | +$8.81K | ﹤0.01% | 8488 |
|
|
2019
Q3 | $90K | Sell |
12,000
-1,000
| -8% | -$9.11K | ﹤0.01% | 8534 |
|
|
2019
Q2 | $121K | Sell |
13,000
-7,500
| -37% | -$54.7K | ﹤0.01% | 8464 |
|
|
2019
Q1 | $108K | Sell |
20,500
-12,600
| -38% | -$71.9K | ﹤0.01% | 8524 |
|
|
2018
Q4 | $147K | Buy |
+33,100
| New | +$181K | ﹤0.01% | 8071 |
|
|
2018
Q3 | – | Sell |
-10,400
| Closed | -$73K | – | 9657 |
|
|
2018
Q2 | $73K | Buy |
+10,400
| New | +$102K | ﹤0.01% | 8353 |
|
Other funds holding SNDX
KCM
VCM
DM
EP
KCM
HRCM
Citadel Advisors's SNDX Position: Q1 2026 in Review
Citadel Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 243% in Q1 2026, buying an estimated $9.71M and bringing the position to 630,942 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.
Citadel Advisors first reported a position in SNDX in Q2 2018 and has held it in 29 quarters since. The position peaked at $49.9M in Q1 2021. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.
- Citadel Advisors held 630,942 shares of Syndax Pharmaceuticals worth $14.7M as of Q1 2026.
- Citadel Advisors bought 446,939 Syndax Pharmaceuticals shares in Q1 2026, an estimated $9.71M.
- Syndax Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2707 holding.
- Citadel Advisors first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
- Citadel Advisors's Syndax Pharmaceuticals position peaked at $49.9M in Q1 2021.
- 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.